A government owned investment firm was considering an investment in a small biopharma company developing a therapeutic monoclonal antibody against a novel immuno-oncology target. Alacrita was asked to assist in a due diligence exercise.
Alacrita's immuno-oncology expert conducted the following activities:
- Reviewed non-clinical data, FIH protocol, clinical development plan and investigator brochure;
- Reviewed literature on the novel target;
- Interviewed company executives; and
- Provided a written overall evaluation and summary of the scientific, clinical and regulatory risks and opportunities in the context of industry benchmark probabilities of success.
The target company successfully raised its Series B investment.Back